These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 31183301)
1. Incidence of Neuroendocrine Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States. Patel N; Benipal B Cureus; 2019 Mar; 11(3):e4322. PubMed ID: 31183301 [TBL] [Abstract][Full Text] [Related]
2. Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States. Patel N; Benipal B Cureus; 2019 Feb; 11(2):e4120. PubMed ID: 31037234 [TBL] [Abstract][Full Text] [Related]
3. Incidence of Pancreatic Adenocarcinoma in the United States from 2001 to 2015: A United States Cancer Statistics Analysis of 50 States. Patel N; Khorolsky C; Benipal B Cureus; 2018 Dec; 10(12):e3796. PubMed ID: 30868010 [TBL] [Abstract][Full Text] [Related]
4. Incidence of Esophageal Cancer in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States. Patel N; Benipal B Cureus; 2018 Dec; 10(12):e3709. PubMed ID: 30788198 [TBL] [Abstract][Full Text] [Related]
5. Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States. Patel N; Benipal B Cureus; 2019 Jan; 11(1):e3962. PubMed ID: 30956914 [TBL] [Abstract][Full Text] [Related]
6. Early-Onset Colorectal Cancer: Are Neuroendocrine Tumors or Adenocarcinomas the Culprit? Analysis of the Largest U.S. Cancer Incidence Database, 2001-2020. Abboud Y; Fraser M; Qureshi I; Hajifathalian K J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398411 [TBL] [Abstract][Full Text] [Related]
7. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. Tsikitis VL; Wertheim BC; Guerrero MA J Cancer; 2012; 3():292-302. PubMed ID: 22773933 [TBL] [Abstract][Full Text] [Related]
8. The rising incidence of major salivary gland cancer in the United States. Del Signore AG; Megwalu UC Ear Nose Throat J; 2017 Mar; 96(3):E13-E16. PubMed ID: 28346649 [TBL] [Abstract][Full Text] [Related]
9. Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. Gittleman H; Ostrom QT; Farah PD; Ondracek A; Chen Y; Wolinsky Y; Kruchko C; Singer J; Kshettry VR; Laws ER; Sloan AE; Selman WR; Barnholtz-Sloan JS J Neurosurg; 2014 Sep; 121(3):527-35. PubMed ID: 24926650 [TBL] [Abstract][Full Text] [Related]
10. Trends in incidence and survival in patients with gastrointestinal neuroendocrine tumors: A SEER database analysis, 1977-2016. Liu M; Wei L; Liu W; Chen S; Guan M; Zhang Y; Guo Z; Liu R; Xie P Front Oncol; 2023; 13():1079575. PubMed ID: 36776304 [TBL] [Abstract][Full Text] [Related]
11. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Fraenkel M; Kim M; Faggiano A; de Herder WW; Valk GD; Endocr Relat Cancer; 2014 Jun; 21(3):R153-63. PubMed ID: 24322304 [TBL] [Abstract][Full Text] [Related]
12. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Modlin IM; Champaneria MC; Chan AK; Kidd M Am J Gastroenterol; 2007 Jul; 102(7):1464-73. PubMed ID: 17391319 [TBL] [Abstract][Full Text] [Related]
13. Increased incidence of early onset colorectal adenocarcinoma is accompanied by an increased incidence of rectal neuroendocrine tumors. Lumsdaine CT; Liu-Smith F; Li X; Zell JA; Lu Y Am J Cancer Res; 2020; 10(6):1888-1899. PubMed ID: 32642298 [TBL] [Abstract][Full Text] [Related]
14. The acceleration in papillary thyroid cancer incidence rates is similar among racial and ethnic groups in the United States. Aschebrook-Kilfoy B; Kaplan EL; Chiu BC; Angelos P; Grogan RH Ann Surg Oncol; 2013 Aug; 20(8):2746-53. PubMed ID: 23504142 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019). Alkhayyat M; Saleh MA; Coronado W; Abureesh M; Zmaili M; Qapaja T; Almomani A; Khoudari G; Mansoor E; Cooper G Ann Gastroenterol; 2021; 34(5):713-720. PubMed ID: 34475743 [TBL] [Abstract][Full Text] [Related]
16. Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic. Rose DB; Nellesen D; Neary MP; Cai B J Med Econ; 2017 Apr; 20(4):395-404. PubMed ID: 27981858 [TBL] [Abstract][Full Text] [Related]
17. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Chen AY; Jemal A; Ward EM Cancer; 2009 Aug; 115(16):3801-7. PubMed ID: 19598221 [TBL] [Abstract][Full Text] [Related]
18. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
19. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease? Fitzgerald TL; Dennis SO; Kachare SD; Vohra NA; Zervos EE Surgery; 2015 Aug; 158(2):466-71. PubMed ID: 26013986 [TBL] [Abstract][Full Text] [Related]
20. Italian cancer figures, report 2012: Cancer in children and adolescents. ; ; Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]